Download PDF
TumorDiagnostik & Therapie 2025; 46(04): 239-243
DOI: 10.1055/a-2453-8742
Übersicht
Schwerpunkt

ALL im Alter: Herausforderungen und maßgeschneiderte Therapieoptionen

Osama Ahmad
,
Claudia Lengerke
› Further Information
Also available at
    Permissions and Reprints

Die akute lymphatische Leukämie (ALL) ist eine seltene, aber aggressive Form von Blutkrebs, deren Behandlung bei älteren Patienten besondere Herausforderungen mit sich bringt. Die Komplexität der Therapie erfordert maßgeschneiderte Ansätze, die auf dem Alter, genetischen Markern wie dem Philadelphia-Chromosom und Komorbiditäten basieren. Der Artikel beleuchtet die Herausforderungen und individuellen Therapieoptionen der ALL im Alter.

Schlüsselwörter

ALL - biologisches Alter - Philadelphia-Chromosom - MRD - maßgeschneiderte Therapie


Publication History

Article published online:
02 May 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute; 2024 Apr 17. [updated: 2024 Nov 5; cited 2025 Mar 11]. https://seer.cancer.gov/statistics-network/explorer/
    PubMed
  • 2 Gokbuget N. Treatment of Older Patients with Acute Lymphoblastic Leukaemia. Drugs Aging 2018; 35: 11-26
    CrossrefPubMedSearch in Google Scholar
  • 3 Bassan R, Brüggemann M, Radcliffe HS. et al. A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia. Haematologica 2019; 104: 2028-2039
    CrossrefPubMedSearch in Google Scholar
  • 4 Jain N, Lamb AV, O’Brien S. et al. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood 2016; 127: 1863-1869
    CrossrefPubMedSearch in Google Scholar
  • 5 Gökbuget N, Boissel N, Chiaretti S. et al. Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood 2024; 143: 1891-1902
    CrossrefPubMedSearch in Google Scholar
  • 6 Rousselot P, Coude MM, Gokbuget N. et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood 2016; 128: 774-782
    CrossrefPubMedSearch in Google Scholar
  • 7 Ottmann OG, Wassmann B, Pfeifer H. et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL). Cancer-Am Cancer Soc 2007; 109: 2068-2076
    CrossrefPubMedSearch in Google Scholar
  • 8 Mauro MJ, Cortes JE, Hochhaus A. et al. Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials. Blood 2014; 124
    CrossrefPubMedSearch in Google Scholar
  • 9 Kantarjian H, Stein A, Gökbuget N. et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. New Engl J Med 2017; 376: 836-847
    CrossrefPubMedSearch in Google Scholar
  • 10 Foa R, Bassan R, Vitale A. et al. Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. N Engl J Med 2020; 383: 1613-1623
    CrossrefPubMedSearch in Google Scholar
  • 11 Shah BD, Ghobadi A, Oluwole OO. et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 2021; 398: 491-502
    CrossrefPubMedSearch in Google Scholar